Munich - Delayed Quote EUR

Iovance Biotherapeutics Inc (2LB.MU)

1.9688

0.0000

(0.00%)

As of 8:01:17 AM GMT+2. Market Open.

Iovance Biotherapeutics to Present at Upcoming Conference

SAN CARLOS, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conference: Goldman Sachs Global Healthcare ConferenceFireside Chat: June 11, 2025 at 1:20 p.m. ETMiami, FL The live and archived webcasts will be available at http

GlobeNewswire 2 days ago

IOVA
The Journal of Clinical Oncology Publishes Five-year Analysis of Amtagvi® (lifileucel) in Patients with Advanced Melanoma

One-time Amtagvi Treatment Continues to Show Deep, Durable Responses and Meaningful Survival One Third of Responses Remain Ongoing without Subsequent Treatment after Five Years Simultaneous Presentation at ASCO 2025 SAN CARLOS, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today anno

GlobeNewswire 10 days ago

IOVA
Iovance Presents Five-Year Amtagvi Data at ASCO for Advanced Melanoma

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) presented five-year data from its Phase 2 C-144-01 trial of Amtagvi (lifileucel) during the 2025 ASCO Annual Meeting. A five-year overall survival rate of 19.7% and a median overall survival of 13.9 months were reported in 153 patients with advanced melanoma who had previously received anti-PD-1 and targeted treatments. The intended […]

Insider Monkey 21 days ago

IOVA
Iovance Announces Five-year Results of Amtagvi® (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting

One-time Amtagvi Treatment Demonstrated Durable Responses and a Five-year Overall Survival Rate of 20% Five-year Follow Up is Unprecedented for Any Therapy in Patients with Advanced Melanoma Previously Treated with Immune Checkpoint Inhibitor SAN CARLOS, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patien

GlobeNewswire 21 days ago

IOVA
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030

Vertex Pharmaceuticals should have big winners with pain drug Journavx and two promising pipeline candidates. Summit Therapeutics is poised for major success with its cancer immunotherapy, ivonescimab. People need healthcare products and services regardless of what's happening with the economy.

Motley Fool 23 days ago

VRTX

SMMT

IOVA
Why Iovance Biotherapeutics Tumbled by Nearly 6% Today

An analyst changed his recommendation on the company, and not for the better. Iovance Biotherapeutics (NASDAQ: IOVA) didn't quite end the stock trading week on a high note. The company's shares were dinged by almost 6% that day, due largely to an analyst's recommendation downgrade.

Motley Fool 27 days ago

IOVA
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SAN CARLOS, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on May 15, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 278,770 shares of Iovance’s common stock to 59 new, non-executi

GlobeNewswire 27 days ago

IOVA
Iovance Biotherapeutics (NasdaqGM:IOVA) Faces Legal Action Amid Revenue Guidance Cut

Iovance Biotherapeutics (NasdaqGM:IOVA) faced a challenging week, experiencing a share price decrease of 45% following the release of disappointing Q1 2025 financial results and a significant downward revision of its full-year revenue guidance. This downturn was compounded by the filing of a class action lawsuit alleging misleading statements about the company's business operations. These developments contrasted sharply with broader market trends, where major indexes like the S&P 500 and Dow...

Simply Wall St. 27 days ago

IOVA
Why Iovance Biotherapeutics (IOVA) Is Among the Best Low Priced Biotech Stocks to Buy Now

We recently published a list of 10 Best Low Priced Biotech Stocks to Buy Now. In this article, we are going to take a look at where Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) stands against other best low priced biotech stocks to buy now. Is Now the Time to Buy Biotech Stocks? On May 8, Michael Yee, […]

Insider Monkey 30 days ago

IOVA
Need To Know: Analysts Just Made A Substantial Cut To Their Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Estimates

One thing we could say about the analysts on Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA ) - they aren't optimistic...

Simply Wall St. last month

IOVA
3 Monster Stocks in the Making

Axsome Therapeutics is taking off, led by a treatment for major depressive disorder. Iovance Biotherapeutics could transform how solid tumors are treated. Here's why they think Axsome Therapeutics (NASDAQ: AXSM), Iovance Biotherapeutics (NASDAQ: IOVA), and Viking Therapeutics (NASDAQ: VKTX) are monster stocks in the making.

Motley Fool last month

VKTX

IOVA

AXSM
Iovance Biotherapeutics First Quarter 2025 Earnings: Misses Expectations

Iovance Biotherapeutics ( NASDAQ:IOVA ) First Quarter 2025 Results Key Financial Results Revenue: US$49.3m (up by...

Simply Wall St. last month

IOVA
Iovance Biotherapeutics Stock Sinks 46%. Here’s Why the Biotech Is Tumbling.

Iovance Biotherapeutics stock was tumbling Friday after the oncology drug maker posted a wider-than-expected first-quarter loss. Management pinned the disappointing first-quarter results on reduced production capacity due to annual maintenance at its Iovance Cell Therapy Center. “Since full production has now resumed at the [Cell Therapy Center], we now expect infusions to grow in the second quarter as compared to the first quarter,” said interim CEO Frederick Vogt.

Barrons.com last month

IOVA
Why Iovance Biotherapeutics Stock Is Crashing Today

Iovance's Q1 revenue was sharply lower than expected. The company blamed the miss on lower production capacity due to annual maintenance at its cell therapy facility. Shares of Iovance Biotherapeutics (NASDAQ: IOVA) were crashing 46.6% lower as of 10:40 a.m. ET on Friday.

Motley Fool last month

IOVA
Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut

IOVA reports dismal first-quarter results. The share price plunges after the company significantly lowers its 2025 sales guidance.

Zacks last month

IOVA
Iovance Biotherapeutics Inc (IOVA) Q1 2025 Earnings Call Highlights: Strong Revenue from Antagy ...

Despite a successful US launch of Antagy, Iovance Biotherapeutics Inc (IOVA) faces manufacturing hurdles and revises its revenue outlook.

GuruFocus.com last month

IOVA
Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Misses Revenue Estimates

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of -44% and 38.73%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

IOVA
Iovance Biotherapeutics: Q1 Earnings Snapshot

SAN CARLOS, Calif. AP) — Iovance Biotherapeutics Inc. IOVA) on Thursday reported a loss of $116.2 million in its first quarter.

Associated Press Finance last month

IOVA
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025

1Q25 Total Product Revenue of $49.3M FY25 Total Product Revenue Guidance Revised to $250M-$300M FY25 Operating Expenses Reduced and 2H26 Cash Runway Guidance Maintained 2025 Regulatory Approvals for Amtagvi® Expected in the UK, EU, and Canada On Track to Report Updated Clinical Data for Registrational Trialin Previously Treated Advanced NSCLC in 2H25 SAN CARLOS, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on in

GlobeNewswire last month

IOVA
Iovance Biotherapeutics (NasdaqGM:IOVA) Sees 3% Price Increase Over Last Month

Iovance Biotherapeutics (NasdaqGM:IOVA) saw a 3% increase in its share price over the last month. This rise occurred amidst mixed market conditions where broader indices displayed minimal movement, as investors awaited crucial updates from the Federal Reserve on interest rates and tariff negotiations between the U.S. and China. Although the company-specific news remains undisclosed, the overall market sentiment, marked by volatility in tech stocks and investor cautiousness towards economic...

Simply Wall St. last month

IOVA

Performance Overview

Return	2LB.MU	S&P 500 (^GSPC)
YTD	-72.32%	+2.78%
1-Year	-75.19%	+11.25%
3-Year	-75.01%	+61.22%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Iovance Biotherapeutics Inc (2LB.MU)

Iovance Biotherapeutics to Present at Upcoming Conference

The Journal of Clinical Oncology Publishes Five-year Analysis of Amtagvi® (lifileucel) in Patients with Advanced Melanoma

Iovance Presents Five-Year Amtagvi Data at ASCO for Advanced Melanoma

Iovance Announces Five-year Results of Amtagvi® (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting

Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030

Why Iovance Biotherapeutics Tumbled by Nearly 6% Today

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance Biotherapeutics (NasdaqGM:IOVA) Faces Legal Action Amid Revenue Guidance Cut

Why Iovance Biotherapeutics (IOVA) Is Among the Best Low Priced Biotech Stocks to Buy Now

Need To Know: Analysts Just Made A Substantial Cut To Their Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Estimates

3 Monster Stocks in the Making

Iovance Biotherapeutics First Quarter 2025 Earnings: Misses Expectations

Iovance Biotherapeutics Stock Sinks 46%. Here’s Why the Biotech Is Tumbling.

Why Iovance Biotherapeutics Stock Is Crashing Today

Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut

Iovance Biotherapeutics Inc (IOVA) Q1 2025 Earnings Call Highlights: Strong Revenue from Antagy ...

Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Misses Revenue Estimates

Iovance Biotherapeutics: Q1 Earnings Snapshot

Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025

Iovance Biotherapeutics (NasdaqGM:IOVA) Sees 3% Price Increase Over Last Month

Performance Overview